About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Biosecurity and Bioterrorism: Biodefense Strategy, Practice,
and Science

Co-Editors-in-Chief: Thomas V. Inglesby, MD and D. A. Henderson, MD, MPH

ISSN: 1538-7135 • Published Bimonthly • Online ISSN: 1557-850X

Current Volume: 12

Latest Impact Factor* is 1.618

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Information for Contributors

     

    Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science is a quarterly peer-reviewed journal.  Its purpose is to serve as an international forum for debate and exploration of the key strategic, scientific, and operational issues posed by biological weapons and bioterrorism.  The Journal provides multidisciplinary analyses and perspectives essential to the creation of strategies and programs that can diminish the threat of bioweapons.
     

    The intended audiences for this Journal are those professional communities that have strategic, scientific, or operational responsibilities critical to improving biosecurity, including medicine, public health, law, national security, bioscientific research, agriculture, food safety, and drug and vaccine development.
     

    The Editors encourage submissions to the Journal from professionals in these fields and others who have the responsibility or opportunity to improve biosecurity. Contributors are asked to follow these guidelines:
     

    • Send an outline or letter to jfox@upmc-biosecurity.org summarizing your paper before submitting—or even writing—the paper. We can give you quick feedback on whether the idea fits the journal.
     

    • Do not submit papers that have been published or that are currently being considered by another journal.
     

    • Original articles, reports, and case studies should range from 3,000 to 5,000 words. Leading edge review papers of a scientific concept or technological application of relevance to biodefense or bioweapons development may be up to 5,000 words in length.
     

    • Editorials and commentaries may be on any issues of relevance to the field but should be succinct and include appropriate documentation. Letters to the Editors intended for publication should be no more than 500 words and may be edited.
     

    • Avoid jargon and overly technical presentations. Our readers come from a number of different fields, and your article should be understandable to well-informed, intelligent readers from various disciplines.
     

    • In addition to presenting the methods and results of a study, you should draw implications from the results and discuss their relevance.
     

    • All authors and co-authors, by definition, are responsible for a significant part of the manuscript. All authors should have taken part in writing the paper, reviewing it, and revising its intellectual and technical content.  Any author whose name appears on a paper assumes responsibility and accountability for the content. All authors will be required to sign a copyright release form.

    CONFLICT OF INTEREST

    Authors must disclose any potential conflict of interest, financial or otherwise, when submitting a manuscript.  Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.


    Submission Guidelines

     

    Manuscripts must be submitted online using the following url: 

    http://mc.manuscriptcentral.com/biosecurity

     

    • Submit all manuscripts double blinded and do not put your name on every page.
     
    • All material published in the journal is copyrighted by Mary Ann Liebert, Inc., including print and electronic rights. This ensures that requests from third parties to reproduce papers are handled efficiently and consistently and will also allow the material to be as widely disseminated as possible. Forms for this purpose will be sent to authors when manuscripts have been accepted for publication. Authors may use their own material in other publications, provided that the Journal is acknowledged as the original place of publication and that the publisher is notified in advance.

    CONSIDERATION OF INFORMATION THAT MIGHT INCREASE THE RISKS ASSOCIATED WITH POTENTIAL BIOWEAPON ATTACKS
     

    Biosecurity and Bioterrorism was created to foster discussion of biosecurity and bioterrorism issues and to promote informed biodefense decision making amongst policymakers, technical experts, and the public.  However, the editors recognize that, in the process of promoting this critical debate, some of the articles published in this journal may contain information, such as public health biodefense preparedness vulnerabilities, biotechnologies, experimental methodologies, and medical response capacities, that could arguably lower the barriers to bioweapons attacks and/or increase the potential consequences of those attacks.  There exists a recognized and important tension between academic freedom and the potential for misapplication of scientific and other knowledge.  Judgments must be made regarding the balancing of risks against the importance of an open, robust debate on these topics.
     

    Given that essentially all biological science information is currently unclassified and available on the worldwide web and that medical and public health planning efforts are largely proceeding in the public domain, the editors believe that it will be a rare occasion that a decision not to publish potentially sensitive information will occur.  While editorial procedures are in place to ensure such actions can occur should they be necessary, the editors have a strong commitment against withholding scientific or other information unless there are clear and compelling reasons to do so.

     

    Preparation of Manuscripts
     

    • Type the entire manuscript, including tables and figure legends, double-spaced with 1-inch margins on all sides. Number pages consecutively.
     

    • Title page.  The title page should have a title of about 45 characters (including spaces).  Do not include authors’ names on this page or subsequent pages.

    • Abstract.  The abstract should state the topic of the article and provide a summary of its main points. It should not exceed 250 words.
     

    • Text.  Insert appropriate subheads in the text. A typical research article will have an introduction, material and methods, results, discussion, acknowledgments, and references. Policy articles, commentaries, and other types of articles should include appropriate subheads.
     

    • Acknowledgments.  Authors should acknowledge only those people and institutions that have made substantive contributions to the study. Details of sources of funding must be given, and any potential conflicts of interest must be declared (e.g., financial, personal, political, or academic).

    • References.  The references should be cited in the text using the numerical order of citation method. The reference list should be at the end of the paper, double-spaced, and organized numerically by order of citation. References should be presented according to the style of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Vancouver style)  [http://www.icmje.org/], as shown below:
     

                Journal article
                Chadee DD, Kitron U. Spatial and temporal patterns of imported malaria cases and local transmission in Trinidad. Am J Trop Med Hyg 1999;61:513-7.

                Book
                Fish D. Population ecology of Ixodes dammin. In: Ginsberg H, ed. Ecology and Environmental Management of Lyme Disease. Rutgers, NJ: Rutgers University Press;1993:25-42.
     

    • Tables.  Submit each table as a separate file. Use Arabic numerals to number tables. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes.
     

    • Illustrations.  Cite figures consecutively within the manuscript.
     

    Please follow these guidelines for submitting artwork:


    • Do NOT embed art files into a Word or PDF document.
    • Line illustrations should be submitted at 1200 dpi.
    • Halftones and color should be submitted at a minimum of 300 dpi.
    • Save as either TIFF or EPS files.
    • Color art must be saved as CYMK - not RGB.
    • Black and White art must be submitted as grayscale – not RGB.
    • Do NOT submit PowerPoint, PDF, Bitmap or Excel files.

    Please name your artwork files with the submitting authors name i.e. SmithFig1.tif, SmithTable2.tif etc. Authors who do not follow these guidelines may have their submission returned to them without being reviewed.

    You will be given directions on how to correct any files which do not pass.
     

    ADDITIONAL INFORMATION ABOUT ART FILES
     

    Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:
     

    • All files should be scanned at 100% size.
    • 300 dpi
    • Final color mode: cmyk
    • save file as: .tif or .eps
     
    If you need directions on how to convert a Power Point slide to acceptable format go to http://www.liebertpub.com/MEDIA/pdf/ppconvert.pdf
     

    • Permissions.  Figures, tables, and text taken from other sources must be accompanied by a written statement from both author and publisher of the original material granting permission for reproduction. Include permission from authors to cite unpublished data or papers still in press.
     

    • Reprints.  Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
     

    Publisher

    The journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215; Telephone: (914) 740–2100; fax: (914) 740–2108; e-mail: info@liebertpub.com; web site: www.liebertpub.com.

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Vector-Borne and Zoonotic Diseases

    Vector-Borne and Zoonotic Diseases

    The first authoritative peer-reviewed journal providing basic and applied research on diseases transmitted to humans by invertebrate vectors or non-human vertebrates.

    Microbial Drug Resistance

    Microbial Drug Resistance

    The international peer-reviewed journal covering the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community.

    Foodborne Pathogens and Disease

    Foodborne Pathogens and Disease

    Spanning an array of issues from "farm-to-fork," this Journal bridges the gap between science and policy to reduce the burden of foodborne illness worldwide.

    Viral Immunology

    Viral Immunology

    The only journal reporting on all aspects of the rapidly growing field of viral immunology, with comprehensive coverage of immune responses to viral infections from basic mechanisms to clinical applications.

Browse All Publications »